FDA approves BioMarin’s gene therapy drug for hemophilia

BioMarin Pharmaceutical Inc.
BMRN,
-3.57%
received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the agency said late Thursday. The FDA said Roctavian was the first gene therapy to treat adults with severe hemophilia A, a serious genetic disorder that affects the gene that makes the protein that causes blood to clot, increasing the risk of uncontrolled bleeding. Shares of BioMarin were up 1% after hours, following a 3.6% decline in the regular session to close at $88.93.